Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure-Reference-Cited by-同舟云学术

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Published:2018-08-01 Issue:8 Volume:99 Page:1058-1065
ISSN:0022-1317
Container-title:Journal of General Virology
language:en
Short-container-title:

Author:

Teraoka Yuji¹²,Uchida Takuro¹²,Imamura Michio¹²,Hiraga Nobuhiko¹²,Osawa Mitsutaka¹²,Kan Hiromi¹²,Saito Yuhei¹²,Tsuge Masataka¹²³,Abe-Chayama Hiromi¹²⁴,Hayes C. Nelson¹²,Makokha Grace Naswa¹²,Aikata Hiroshi¹²,Miki Daiki²⁵,Ochi Hidenori²⁵,Ishida Yuji²⁶,Tateno Chise²⁶,Chayama Kazuaki¹²⁵

Affiliation:

1. 1Department of Gastroenterology and Metabolism, Institute of Biomedical and Health, Hiroshima, Japan

2. 2Liver Research Project Center, Hiroshima University, Hiroshima, Japan

3. 3Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan

4. 4Center for Medical Specialist Graduate Education and Research, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

5. 5Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences, Hiroshima, Japan

6. 6PhoenixBio Co., Ltd, Higashihiroshima, Japan

Publisher

Microbiology Society

Subject

Virology

Reference30 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Virologic and Clinical Expressions of Reciprocal Inhibitory Effect of Hepatitis B, C, and Delta Viruses in Patients With Chronic Hepatitis

3. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

4. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on direct antiviral agents for the treatment of hepatitis C;Expert Opinion on Pharmacotherapy;2021-05-11

2. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C;JHEP Reports;2020-10

3. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection;Clinical Journal of Gastroenterology;2020-07-12

4. Structure-activity relationships of fluorene compounds inhibiting HCV variants;Antiviral Research;2020-02

5. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C;Expert Opinion on Pharmacotherapy;2020-01-08